Skip to main content
. 2010 Sep 22;45(1):31–39. doi: 10.2478/v10019-010-0041-9

Table 2.

Details of EGT treatment and response to therapy

Pt No. Nodule Tumor volume before EGT (cm3) Tumor volume after EGT1 (cm3) No. of sessions Dose of pIL12 per EGT session (mg) Dose of plasmid per body weight (mg/kg)2 Post EGT therapy Follow up after 1st EGT (months) Response at the end of follow up
1 1 0.25 0.1 2 0.15/0.15 0.05 / 36 SD Euth., not related to MCT
2 1 2.3 2.0 1 0.5 0.01 Surgery 24 CR without recurrence
3 1 3.2 1.6 2 1.0/1.0 0.12 CCNU (4 cycles) 12 SD stable disease
4 1 0.6 0.3 2 0.5/0.2 0.06 ECT 13 CR without recurrence
2 1.2 0.8 2 0.5/0.4 Surgery CR without recurrence
5 1 2.9 0.6 2 0.5/0.5 0.03 Surgery 10 CR without recurrence
6 1 0.03 0.005 4 0.1/0.1/0.1/0.1 0.07 / 44 SD stable disease
2 0.27 0.08 4 0.25/0.25/0.25/0.25 / SD
7 1 25.4 18.0 3 1.0/0.6/0.6 0.12 Surgery 2 PD Euth. due to PD
8 1 0.45 0.6 1 0.2 0.025 CCNU (3 cycles) 5 PD Euth. due to PD
2 0.03 0.03 1 0.1

Euth, euthanasia; MCT, mast cell tumor; CR, complete response; CCNU, lomustine; ECT, electrochemotherapy; SD, stable disease; PD, progressive disease

1

The smallest volume of tumor nodule, achieved 1 week after the last performed EGT session

2

Cumulative dose of received plasmid per kg of body weight